GO
Loading...

Stock in 60 Seconds: Daiichi Sankyo and ArQule

Tuesday, 2 Oct 2012 | 11:10 PM ET

CNBC's Adam Bakhtiar takes on the challenge of the daily stock in 60 seconds segment and looks at Daiichi Sankyo and ArQule, where the latter's shares plunged plunged after it revealed that it would discontinue the late-stage trial of the lung cancer drug that it was co-developing with Daiichi.